Literature DB >> 20222714

Complexity in influenza virus targeted drug design: interaction with human sialidases.

Leonard M G Chavas1, Ryuichi Kato, Nobuhiro Suzuki, Mark von Itzstein, Maretta C Mann, Robin J Thomson, Jeffrey C Dyason, Jennifer McKimm-Breschkin, Paola Fusi, Cristina Tringali, Bruno Venerando, Guido Tettamanti, Eugenio Monti, Soichi Wakatsuki.   

Abstract

With the global spread of the pandemic H1N1 and the ongoing pandemic potential of the H5N1 subtype, the influenza virus represents one of the most alarming viruses spreading worldwide. The influenza virus sialidase is an effective drug target, and a number of inhibitors are clinically effective against the virus (zanamivir, oseltamivir, peramivir). Here we report structural and biochemical studies of the human cytosolic sialidase Neu2 with influenza virus sialidase-targeting drugs and related compounds.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20222714     DOI： 10.1021/jm100078r

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


  9 in total

1.  Clinical reasoning: an unexpected diagnosis in a 4-month-old infant with lethargy and H1N1 influenza.

Authors:  Ann E Hyslop; Brian S Droker; Laura A Jansen
Journal:  Neurology       Date:  2011-05-03       Impact factor: 9.910

2.  Identifying selective inhibitors against the human cytosolic sialidase NEU2 by substrate specificity studies.

Authors:  Yanhong Li; Hongzhi Cao; Hai Yu; Yi Chen; Kam Lau; Jingyao Qu; Vireak Thon; Go Sugiarto; Xi Chen
Journal:  Mol Biosyst       Date:  2011-01-04

Review 3.  Preventing and treating secondary bacterial infections with antiviral agents.

Authors:  Jonathan A McCullers
Journal:  Antivir Ther       Date:  2011

4.  Anti-influenza neuraminidase inhibitor oseltamivir phosphate induces canine mammary cancer cell aggressiveness.

Authors:  Joana T de Oliveira; Ana L Santos; Catarina Gomes; Rita Barros; Cláudia Ribeiro; Nuno Mendes; Augusto J de Matos; M Helena Vasconcelos; Maria José Oliveira; Celso A Reis; Fátima Gärtner
Journal:  PLoS One       Date:  2015-04-07       Impact factor: 3.240

5.  Synthetic Mucus Nanobarriers for Identification of Glycan-Dependent Primary Influenza A Infection Inhibitors.

Authors:  Miriam Cohen; Hooman P Senaati; Christopher J Fisher; Mia L Huang; Pascal Gagneux; Kamil Godula
Journal:  ACS Cent Sci       Date:  2016-09-29       Impact factor: 14.553

6.  Antibody against Microbial Neuraminidases Recognizes Human Sialidase 3 (NEU3): the Neuraminidase/Sialidase Superfamily Revisited.

Authors:  Chiguang Feng; Jihong Li; Greg Snyder; Wei Huang; Simeon E Goldblum; Wilbur H Chen; Lai-Xi Wang; Bruce A McClane; Alan S Cross
Journal:  MBio       Date:  2017-06-27       Impact factor: 7.867

7.  Novel pH-dependent regulation of human cytosolic sialidase 2 (NEU2) activities by siastatin B and structural prediction of NEU2/siastatin B complex.

Authors:  M Motiur Rahman; Takatsugu Hirokawa; Daisuke Tsuji; Jun Tsukimoto; Seiji Hitaoka; Tatsusada Yoshida; Hiroshi Chuman; Kohji Itoh
Journal:  Biochem Biophys Rep       Date:  2015-09-25

8.  The evolutionary pattern of glycosylation sites in influenza virus (H5N1) hemagglutinin and neuraminidase.

Authors:  Wentian Chen; Yaogang Zhong; Yannan Qin; Shisheng Sun; Zheng Li
Journal:  PLoS One       Date:  2012-11-01       Impact factor: 3.240

9.  The impact of the butterfly effect on human parainfluenza virus haemagglutinin-neuraminidase inhibitor design.

Authors:  Larissa Dirr; Ibrahim M El-Deeb; Leonard M G Chavas; Patrice Guillon; Mark von Itzstein
Journal:  Sci Rep       Date:  2017-07-03       Impact factor: 4.379
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.